Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading IDRA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.29%72.681.2%$696.93m
CELGCelgene Corporation
-4.32%112.321.3%$648.03m
AMGNAmgen Inc.
-2.83%141.001.0%$609.20m
BIIBBiogen Inc.
-2.33%284.391.2%$526.99m
REGNRegeneron Pharmaceuticals, Inc.
-3.57%355.803.6%$379.95m
ALXNAlexion Pharmaceuticals, Inc.
0.15%124.351.9%$361.62m
ILMNIllumina, Inc.
-3.51%121.973.0%$177.15m
VRTXVertex Pharmaceuticals Incorporated
-3.66%75.262.9%$163.89m
INCYIncyte Corporation
-4.18%102.722.4%$160.87m
TSROTESARO, Inc.
-3.00%135.6817.1%$155.70m
IONSIonis Pharmaceuticals, Inc.
-4.26%45.4310.0%$146.45m
EXELExelixis, Inc.
-8.88%16.636.4%$116.59m
BMRNBioMarin Pharmaceutical Inc.
-2.04%81.304.5%$113.90m
BLUEBluebird Bio, Inc.
-9.37%71.5523.3%$112.28m
AAgilent Technologies, Inc.
-0.41%44.661.6%$111.16m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.